NeoBiotechnologies is a leading manufacturer and original supplier of highly validated monoclonal and recombinant antibodies for research and diagnostic applications. With a portfolio of over 10'000 in‑house–developed antibodies, the company is known for its exceptionally stringent validation standards, including HuProt™ human protein microarray screening to ensure specificity, reproducibility, and reliability. NeoBiotechnologies’ products are widely trusted by researchers and institutions worldwide, particularly in cancer, immuno‑oncology, and translational research.
Product Portfolio
- Monoclonal antibodies (mouse, rabbit, and rat), produced via hybridoma and recombinant technologies with lot-to-lot consistency
- Recombinant monoclonal antibodies, optimized for precision, scalability, and reproducibility in research and diagnostic assays
- HuProt™-validated antibodies, screened against over 21,000 full-length human proteins to ensure monospecificity
- Immunohistochemistry (IHC)–validated antibodies for tissue-based protein detection in oncology and pathology research
- Cancer and disease marker antibodies, including targets for breast, colon, lung, prostate, ovarian, and pancreatic cancer research
- Transcription factor antibodies, developed under NIH-supported programs for gene regulation research
